Crossmark

Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-021-05587-w

Published Online: 2021-09-20

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yaqub, Sheraz https://orcid.org/0000-0002-5696-2319
Bjørnbeth, Bjørn Atle

Angelsen, Jon-Helge

Fristrup, Claus Wilki

Grønbech, Jon Erik

Hemmingsson, Oskar

Isaksson, Bengt

Juel, Ingebjørg Soterud

Larsen, Peter Nørgaard

Lindell, Gert

Mortensen, Frank Viborg

Mortensen, Kim Erlend

Rizell, Magnus

Sandström, Per

Sandvik, Oddvar Mathias

Sparrelid, Ernesto

Taflin, Helena

Taskén, Kjetil

,

Brudvik, Kristoffer W.

Fretland, Åsmund A.

Horn, Arild

Kleive, Dyre

Labori, Knut J.

Lassen, Kristoffer

Røsok, Bård I.

Søreide, Jon A.

Tholfsen, Tore

Villanger, Olaug

Waage, Anne
Funding

Funding for this research was provided by:

Kreftforeningen (182788)

Norges Forskningsråd (235340)

Helse Sør-Øst RHF (2016201)
License Information

Text and Data Mining valid from 2021-09-20

Version of Record valid from 2021-09-20
More Information

Article History

Received: 15 December 2020

Accepted: 31 August 2021

First Online: 20 September 2021

Declarations

:

: The Regional Committee for Medical and Health Research Ethics has reviewed and approved the Research Project (Norway 2014/2217 REK sør-øst B; Sweden 2017/559-32; Denmark H-17040958).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below